Amarin Corp Plcuk (AMRN) Income towards Parent Company (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Income towards Parent Company of -$10.5 million for Q1 2026, up 33.03% year-over-year from -$7.9 million in Q1 2025, and down 758.82% quarter-over-quarter from -$1.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Income towards Parent Company (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Income towards Parent Company data on file, last reported at -$10.5 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$10.5 million, up 33.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.6 million (down 109.94% YoY), and the FY2025 annual result was -$38.8 million, down 277.89% from the prior year.
- Income towards Parent Company eased to -$10.5 million in Q1 2026 per AMRN's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $110.0 million in Q4 2022 and troughed at -$70.0 million in Q2 2022.
- A 5-year average of -$6.8 million and a median of -$10.5 million in 2026 frame the typical range for Income towards Parent Company.
- On a YoY basis, Income towards Parent Company climbed as much as 648.53% in 2022 and fell as far as 1841.14% in 2022.
- A 5-year view of Income towards Parent Company shows it stood at $110.0 million in 2022, then sank by 105.25% to -$5.8 million in 2023, then soared by 503.01% to $23.3 million in 2024, then slumped by 105.25% to -$1.2 million in 2025, then sank by 758.82% to -$10.5 million in 2026.
- Business Quant data shows AMRN's Income towards Parent Company at -$10.5 million in Q1 2026, -$1.2 million in Q4 2025, and -$7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | -5.78 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 110.02 Mn |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 14.70 Mn |
| Sep 30, 2021 | -13.15 Mn |
| Jun 30, 2021 | 7.81 Mn |